{"id":"nirsevimab","rwe":[],"_fda":{"id":"e0a65d86-3032-4442-86be-8bd9f01639e9","set_id":"2f08fa60-f674-432d-801b-1f9514bd9b39","openfda":{"nui":["N0000175623","N0000175615"],"unii":["VRN8S9CW5V"],"route":["INTRAMUSCULAR"],"rxcui":["2642406","2642412","2642414","2642415"],"spl_id":["e0a65d86-3032-4442-86be-8bd9f01639e9"],"brand_name":["BEYFORTUS"],"spl_set_id":["2f08fa60-f674-432d-801b-1f9514bd9b39"],"package_ndc":["49281-575-00","49281-575-15","49281-574-88","49281-574-15"],"product_ndc":["49281-574","49281-575"],"generic_name":["NIRSEVIMAB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["NIRSEVIMAB"],"pharm_class_epc":["Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]"],"pharm_class_moa":["Fusion Protein Inhibitors [MoA]"],"manufacturer_name":["Sanofi Pasteur Inc."],"application_number":["BLA761328"],"is_original_packager":[true]},"version":"24","pregnancy":["8.1 Pregnancy BEYFORTUS is not indicated for use in females of reproductive potential."],"overdosage":["10 OVERDOSAGE There is limited experience of overdose with BEYFORTUS. There is no specific treatment for an overdose with BEYFORTUS. In the event of an overdose, the individual should be monitored for the occurrence of adverse reactions and provided with symptomatic treatment as appropriate."],"description":["11 DESCRIPTION Nirsevimab-alip, a respiratory syncytial virus F protein-directed fusion inhibitor, is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The molecular weight is approximately 146.3 kDa. BEYFORTUS (nirsevimab-alip) injection is a sterile, preservative-free, clear to opalescent, colorless to yellow solution for intramuscular injection. It is supplied in a single-dose siliconized Luer lock Type I glass pre-filled syringe with a FluroTec coated plunger stopper. Each 0.5 mL contains 50 mg nirsevimab-alip, arginine hydrochloride (8 mg), histidine (1.1 mg), L-histidine hydrochloride monohydrate (1.6 mg), polysorbate 80 (0.1 mg), sucrose (21 mg), and water for injection (USP). The pH is 6.0. Each 1 mL contains 100 mg nirsevimab-alip, arginine hydrochloride (17 mg), histidine (2.2 mg), L-histidine hydrochloride monohydrate (3.3 mg), polysorbate 80 (0.2 mg), sucrose (41 mg), and water for injection (USP). The pH is 6.0."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied BEYFORTUS injection is a sterile, preservative-free, clear to opalescent, colorless to yellow solution supplied as follows: One 50 mg/0.5 mL single-dose pre-filled syringe in a carton: NDC 49281-575-00 Five 50 mg/0.5 mL single-dose pre-filled syringes in a carton: NDC 49281-575-15 One 100 mg/mL single-dose pre-filled syringe in a carton: NDC 49281-574-88 Five 100 mg/mL single-dose pre-filled syringes in a carton: NDC 49281-574-15 Each BEYFORTUS pre-filled syringe is for one time use only. Storage and Handling Store refrigerated between 36°F to 46°F (2°C to 8°C). BEYFORTUS may be kept at room temperature 68°F to 77°F (20°C to 25°C) for a maximum of 8 hours. After removal from the refrigerator, BEYFORTUS must be used within 8 hours or discarded. Store BEYFORTUS in original carton to protect from light until time of use. Do not freeze. Do not shake. Do not expose to heat."],"microbiology":["12.4 Microbiology Mechanism of Action Nirsevimab-alip is a recombinant human IgG1κ monoclonal antibody that provides passive immunity by targeting the prefusion conformation of the RSV F protein. Nirsevimab-alip is long-acting due to a triple amino acid substitution (YTE) in the Fc region which increases binding to the neonatal Fc receptor and thereby extends serum half-life. Nirsevimab-alip binds to a conserved epitope in antigenic site Ø on the prefusion protein with dissociation constants K D = 0.12 nM and K D = 1.22 nM for RSV subtype A and B strains, respectively; it neutralizes RSV by inhibiting conformation changes in the F protein necessary for fusion of the viral and cellular membranes and viral entry. Antiviral Activity The cell culture neutralization activity of nirsevimab-alip against RSV was measured in a concentration-response model using cultured Hep-2 cells. Nirsevimab-alip neutralized clinical RSV isolates collected from global locations between 2003 and 2017 with median EC 50 values for RSV A of 21 pM (3.2 ng/mL) (n=70; range 3 pM [0.48 ng/mL] to 100 pM [15 ng/mL]) and for RSV B of 19 pM (2.9 ng/mL) (n=49; range 2 pM [0.3 ng/mL] to 398 pM [59.7 ng/mL]). Antiviral Resistance In Cell Culture Escape variants were selected following three passages in cell culture of RSV A2 and B9320 strains in the presence of nirsevimab-alip. Recombinant RSV A variants that showed reduced susceptibility to nirsevimab-alip compared with the reference strain included those with substitutions N67I+N208Y (103-fold reduction). Recombinant RSV B variants that showed reduced susceptibility to nirsevimab-alip included those with substitutions N208D (>90,000-fold change), N208S (>24,000-fold change), K68N+N201S (>13,000-fold change), and K68N+N208S (>90,000-fold change). All resistance-associated substitutions identified among neutralization escape variants were located in the nirsevimab-alip binding site (amino acids 62–69 and 196–212) and were shown to reduce binding affinity to RSV F protein. In Surveillance Trials Polymorphisms conferring large fold-reductions in susceptibility to nirsevimab-alip in isolates collected from 1956–2014 were not observed for RSV A and seen rarely (<1%) for RSV B, and included K65Q+K68N (1,239-fold change), K65Q+S211N (36-fold change), and L203I (3,005-fold change) substitutions. In prospective, observational, global molecular epidemiology studies (OUTSMART-RSV and INFORM-RSV) genetic diversity of RSV F protein sequences has remained low (most amino acids in both RSV A and RSV B >99% conserved). Variants harboring known nirsevimab-alip resistance-associated substitutions have been rare (<1%) and include RSV B substitutions K68Q (>369-fold change), N201T (>406-fold change) and N201T+I206M+Q209R (>418-fold change). Variants observed with reduced susceptibility include RSV A substitutions K68E (13-fold change), K68N (5-fold change), and S275F (6-fold change), and RSV B substitutions K68N (30-fold change), K68Q+I206M+Q209R (46-fold change), N201S (127-fold change) and N201S+I206M+Q209R (17-fold change). The clinical significance of these reductions in susceptibility is not known. From 2015 to 2021, most amino acid residues in the nirsevimab-alip binding site were highly conserved (>99%) at all positions in RSV A and 22 of the 25 positions in RSV B. Co-occurring substitutions I206M+Q209R in the nirsevimab-alip binding site that have become prevalent in RSV B since 2017 did not confer reduced susceptibility (<5-fold change) to nirsevimab-alip. The S211N substitution which has increased in prevalence also retains susceptibility to nirsevimab-alip, both individually and concurrently with I206M+Q209R. In Clinical Trials In Trial 04, Trial 05 and Trial 08 no known resistance-associated substitutions were identified at ≥25% frequency at any sampling time points. Phenotypic testing of novel substitutions is ongoing. In Trial 03 (who received a single dose of 50 mg BEYFORTUS), 2 of 40 subjects with RSV infections corresponding to any case definition had a variant containing nirsevimab-alip resistance-associated substitutions. The two subjects received less than the recommended nirsevimab-alip dose and had RSV B variants harboring I64T+K68E+I206M+Q209R co-occurring substitutions or an N208S substitution. I64T, K68E, and N208S substitutions individually have reduced susceptibility to nirsevimab-alip (fold changes: >496, >283, and >387, respectively). In Trial 04, an RSV B variant harboring binding site substitution L204S (no phenotypic data) concurrent with I206M+Q209R+S211N substitutions (<5-fold change) was detected at ≥25% frequency in one subject who received BEYFORTUS through Day 150. RSV B variants present at <25% frequency with I64T+K68E substitutions (>280-fold-change) and N208I substitution (>600-fold change) were seen in one subject each who received BEYFORTUS through Day 150 and an RSV B N201D substitution (>613-fold change) was observed in one subject after Day 150. In addition, an RSV A K209E substitution (135-fold change) was observed at <25% frequency in one subject after Day 150. Cross-resistance Limited data are available that show that variants resistant to nirsevimab-alip could have cross-resistance to palivizumab. Palivizumab retained full neutralization potency against resistance-associated substitutions identified in Trial 03 and Trial 04. Nirsevimab-alip retained activity against recombinant RSV harboring palivizumab resistance-associated substitutions identified in molecular epidemiology studies and in neutralization escape variants of palivizumab; S275F substitution had reduced susceptibility of 6-fold."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of BEYFORTUS have been established for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. The safety and efficacy of BEYFORTUS for this indication and populations are discussed throughout the labeling. Use of BEYFORTUS for this indication is supported by evidence from adequate and well-controlled studies in neonates and infants from birth up to 12 months of age with additional pharmacokinetic and safety data in children up to 24 months of age [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14) ]. Use of BEYFORTUS in this population is supported by the following: - Trial 03, a randomized, double-blind, placebo-controlled multicenter trial for the prevention of MA RSV LRTI conducted in preterm infants born at GA greater than or equal to 29 weeks and less than 35 weeks entering their first RSV season; - Trial 04, a double-blind, placebo-controlled multicenter trial, for the prevention of MA RSV LRTI in term and late preterm infants GA greater than or equal to 35 weeks entering their first RSV season; - Trial 05, a Phase 2/3 randomized, double-blind, palivizumab-controlled multicenter trial in pediatric subjects born less than 35 weeks GA and infants with CLD of prematurity or hemodynamically significant CHD entering their first or second RSV season. In addition, BEYFORTUS was evaluated in an open-label, uncontrolled, single-dose trial (Trial 08) in 100 infants and children who were less than or equal to 24 months of age, who received BEYFORTUS in their first or second RSV season, and who had a wide variety of underlying diseases or treatments resulting in immune compromise. The safety profile of BEYFORTUS administered in Trial 08 was consistent with the safety profile of other trials of BEYFORTUS in infants and children [see Clinical Pharmacology (12.3) ]. Trial 09 is a Phase 3b randomized, open-label trial of BEYFORTUS compared to no intervention for the prevention of hospitalization in term and preterm infants (GA greater than or equal to 29 weeks) born during or entering their first RSV season [see Adverse Reactions (6.1) and Clinical Studies (14.5) ]. The safety and effectiveness of BEYFORTUS have not been established in children older than 24 months of age."],"effective_time":"20260112","clinical_studies":["14 CLINICAL STUDIES 14.1 Description of Clinical Trials The efficacy and safety of BEYFORTUS were evaluated in term and preterm infants and children in the trials summarized in Table 4. Table 4 Trials Conducted with BEYFORTUS for the Prevention of MA RSV LRTI Trial Population Study Arms GA gestational age; CLD chronic lung disease; CHD hemodynamically significant chronic heart disease D5290C00003 (Trial 03) NCT02878330 Infants born at ≥29 to <35 weeks GA entering their first RSV season BEYFORTUS (N=969) All subjects in Trial 03 were included in the efficacy analysis. All subjects in Trial 03 received 50 mg of BEYFORTUS IM injections regardless of body weight. The recommended BEYFORTUS dose in neonates and infants born during or entering their first RSV season is single IM 50 mg and 100 mg dose for those who weigh <5 kg and ≥5 kg, respectively [see Dosage and Administration (2.1) ] . Placebo (N=484) D5290C00004 (Trial 04) NCT03979313 Infants born at ≥35 weeks GA entering their first RSV season Primary Cohort The primary efficacy analysis for Trial 04 is based on subjects from the Primary Cohort. For Trial 04 safety population [see Adverse Reactions (6.1) ] . : BEYFORTUS (N=994) Placebo (N=496) Safety Cohort Trial 04 safety analysis included both Primary and Safety Cohorts [see Adverse Reactions (6.1) ] . : BEYFORTUS (N=1,015) Placebo (N=507) D5290C00005 (Trial 05) NCT03959488 Infants born at <35 weeks GA and infants born with CLD or CHD entering their first RSV season RSV Season One: BEYFORTUS (N=616) Palivizumab (N=309) Infants with CLD or CHD only entering their second RSV season RSV Season Two: BEYFORTUS (N=220) Palivizumab (N=42) VAS00006 (Trial 09) NCT05437510 Infants born ≥29 weeks GA entering their first RSV season BEYFORTUS (N=4,016) No intervention (N=4,018) 14.2 Prevention of MA RSV LRTI in Infants Born at ≥29 to <35 Weeks Gestational Age (Trial 03) Trial 03 was a randomized, double-blind, placebo-controlled multicenter trial for the prevention of Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection (MA RSV LRTI) conducted in preterm infants born at gestational age (GA) greater than or equal to 29 weeks and less than 35 weeks. These subjects were randomized 2:1 to receive BEYFORTUS (N=969) or placebo (N=484) by IM injection. All subjects in the BEYFORTUS arm received 50 mg IM of BEYFORTUS regardless of body weight. The recommended BEYFORTUS dose in neonates and infants born during or entering their first RSV season is a single IM 50 mg or 100 mg dose for those who weigh less than 5 kg and greater than or equal to 5 kg, respectively [see Dosage and Administration (2.1) ] . At randomization, 20% were GA greater than or equal to 29 weeks and less than 32 weeks; 80% were GA greater than or equal to 32 and less than 35 weeks; 52% were male; 72% were White; 18% were Black; 1% were Asian; 1% were Pacific Islander, and 8% were Other or Mixed Race; 22% were Hispanic or Latino; 68% were from Northern Hemisphere. The median age was 2.8 months (range: 0.1 to 11.9 months); 53% were less than or equal to 3 months; 33% were greater than 3 to less than or equal to 6 months, and 14% were greater than 6 months of age. The primary endpoint was the incidence of MA RSV LRTI caused by RT-PCR-confirmed RSV, characterized predominantly as bronchiolitis or pneumonia through 150 days after dosing. Medically Attended (MA) includes all healthcare provider visits such as physician office, urgent care, emergency room visits and hospitalizations. Signs of LRTI involvement included rhonchi, rales, crackles, or wheezing; and at least one sign of worsening clinical severity including at least one of the following: increased respiratory rate, hypoxemia, acute hypoxic or ventilatory failure, new onset apnea, nasal flaring, retractions, grunting, or dehydration due to respiratory distress. Incidence of RSV LRTI with hospitalization was a prespecified secondary endpoint. RSV hospitalization was defined as hospitalization for LRTI with a positive RSV test. Table 5 displays the primary efficacy result for Trial 03. Table 5 Incidence of MA RSV LRTI in Infants Born at ≥29 Weeks to <35 Weeks Through 150 Days Post Dose (Trial 03) N Incidence % (n) Efficacy Efficacy for MA RSV LRTI based on relative risk reduction against placebo adjusted for age at randomization and hemisphere. (95% CI) BEYFORTUS 969 2.6% (25) 70.1% (52.3, 81.2) p-value =<0.001. In a post-hoc analysis of all randomized infants in Trial 03 weighing <5 kg at baseline, and who received the recommended dose of BEYFORTUS, efficacy for MA RSV LRTI, based on relative risk reduction against placebo was 86.2% (95% CI 68.0, 94.0); efficacy for RSV LRTI with hospitalization based on relative risk reduction against placebo was 86.5% (95% CI 53.5, 96.1). Placebo 484 9.5% (46) In Trial 03, the efficacy of BEYFORTUS against MA RSV LRTI with hospitalization in infants born at GA greater than or equal to 29 weeks and less than 35 weeks, who received a single dose of 50 mg BEYFORTUS, based on the relative risk reduction was 78.4% (95% CI 51.9, 90.3; p=0.0002), through 150 days post dose. 14.3 Prevention of MA RSV LRTI in Infants Born at ≥35 Weeks Gestational Age (Trial 04) BEYFORTUS was evaluated in one Phase 3 randomized, double-blind, placebo-controlled multicenter trial, Trial 04, for the prevention of MA RSV LRTI in term and late preterm infants GA greater than or equal to 35 weeks entering their first RSV season. The primary analysis population (Primary Cohort) included 1,490 term and late preterm infants (GA greater than or equal to 35 weeks). Subjects were randomized 2:1 to receive a single IM dose of BEYFORTUS (N=994) (50 mg if less than 5 kg body weight or 100 mg if greater than or equal to 5 kg body weight at the time of dosing), or placebo (N=496). At randomization, 14% were GA greater than or equal to 35 weeks and less than 37 weeks; 86% were GA greater than or equal to 37 weeks; 52% were male; 53% were White; 28% were Black; 6% were American Indian/Alaskan native; 4% were Asian; 1% were Pacific Islander; and 8% were Other or Mixed Race; 10% were Hispanic or Latino; 69% were from Northern Hemisphere; and 40% weighed less than 5 kg. The median age was 2.6 months (range: 0.03 to 11.10 months); 58% were less than or equal to 3 months; 32% were greater than 3 to less than or equal to 6 months, and 10% were greater than 6 months of age. In Trial 04, the primary endpoint was the incidence of MA RSV LRTI caused by RT-PCR-confirmed RSV, as defined in Trial 03. Incidence of RSV LRTI with hospitalization was a prespecified secondary endpoint. RSV hospitalization was defined as hospitalization for LRTI with a positive RSV test. Table 6 displays the primary efficacy result from Trial 04. Table 6 Incidence of MA RSV LRTI in Infants Born at ≥35 Weeks Through 150 Days Post Dose (Trial 04) The primary efficacy analysis for Trial 04 is based on subjects from the Primary Cohort. N Incidence % (n) Efficacy Efficacy for MA RSV LRTI based on relative risk reduction against placebo adjusted for age at randomization. (95% CI) BEYFORTUS 994 1.2% (12) 74.9% (50.6, 87.3) p-value =<0.001. Placebo 496 5.0% (25) In Trial 04, the efficacy of BEYFORTUS against MA RSV LRTI with hospitalization in infants born at GA greater than or equal to 35 weeks, who received a single IM 50 mg or 100 mg dose for those who weigh less than 5 kg and greater than or equal to 5 kg, respectively, based on the relative risk reduction was 60.2% (95% CI -14.6, 86.2; p=0.09), through 150 days post dose. 14.4 Prevention of MA RSV LRTI in Infants Born at <35 Weeks Gestational Age and Infants with CLD of Prematurity or Hemodynamically Significant CHD (Trial 05) The safety and PK of BEYFORTUS were evaluated in a Phase 2/3 randomized, double-blind, palivizumab-controlled multicenter trial (Trial 05) in pediatric subjects born less than 35 weeks GA and infants with CLD of prematurity or hemodynamically significant CHD. This trial was not powered for efficacy, but efficacy was assessed as secondary endpoint. The efficacy of BEYFORTUS in preterm infants (GA less than 35 weeks) during their first RSV season and in pediatric subjects up to 24 months of age with CLD or CHD during their first and second RSV season was established by extrapolation of efficacy of BEYFORTUS from Trials 03 and Trial 04 to the population enrolled in Trial 05 based on similar nirsevimab-alip exposures among subjects enrolled in Trial 04 and 05 [see Clinical Pharmacology (12.3) ] . Trial 05: RSV Season One Trial 05 enrolled infants at higher risk for severe RSV disease entering their first RSV season into one of two cohorts: preterm infants (GA less than 35 weeks) and infants with CLD of prematurity or hemodynamically significant CHD. A total of 925 infants were randomized 2:1 in each of the preterm (n=615) and CLD/CHD (n=310) cohorts to receive BEYFORTUS or palivizumab. Infants received a single IM dose of BEYFORTUS (50 mg if less than 5 kg body weight or 100 mg if greater than 5 kg body weight at the time of dosing), followed by 4 once-monthly IM doses of placebo, or 5 once-monthly IM doses of 15 mg/kg palivizumab, respectively. At randomization, in the preterm cohort, 77 infants (13%) were less than 29 weeks GA; and 499 (81%) were GA greater than or equal to 29 to less than 35 weeks. In the CLD/CHD cohort, 70% had CLD of prematurity; 34% had hemodynamically significant CHD; 123 infants (40%) were less than 29 weeks GA, 28% were greater than or equal to 29 weeks to less than 35 weeks GA; and 32% were greater than or equal to 35 weeks GA. In both cohorts together, 54% were male; 79% were White; 10% were Black; 5% were Asian; 2% were American Indian/Alaskan Native; 15% were Hispanic or Latino; and 57% weighed less than 5 kg. The median age was 3.5 months (range: 0.07 to 12.3 months); 45% were less than or equal to 3 months; 34% were greater than 3 months to less than or equal to 6 months, and 21% were greater than 6 months of age. In the first RSV season of Trial 05, the incidence of MA RSV LRTI through 150 days post dose was 0.6% (4/616) in the BEYFORTUS group and 1.0% (3/309) in the palivizumab group. Trial 05: RSV Season Two Pediatric subjects with CLD of prematurity or hemodynamically significant CHD up to 24 months of age continued in the trial for a second RSV season (n=262). Subjects who received BEYFORTUS during their first RSV season also received a single dose of 200 mg BEYFORTUS entering their second RSV season followed by 4 once-monthly IM doses of placebo (n=180). Subjects who received palivizumab during their first RSV season were re-randomized 1:1 to either receive BEYFORTUS or palivizumab entering their second RSV season. Forty subjects who received palivizumab in the first RSV season received a single IM dose of BEYFORTUS followed by 4 once-monthly IM doses of placebo in their second RSV season; and 42 subjects received palivizumab (5 once-monthly IM doses of 15 mg/kg palivizumab) in both first and second RSV seasons. In the second RSV season of Trial 05, there were no cases of MA RSV LRTI through Day 150 post-dose in subjects who received either BEYFORTUS or palivizumab. 14.5 Prevention of RSV LRTI Hospitalization in Term and Preterm Infants (Trial 09) Trial 09 is a Phase 3b, randomized open-label trial consisting of 8,058 term and preterm infants (GA greater than or equal to 29 weeks) born during or entering their first RSV season who received either a single IM dose of BEYFORTUS (50 mg if less than 5 kg body weight or 100 mg if greater than or equal to 5 kg body weight at the time of dosing) or no intervention. The trial was conducted under real world conditions in the United Kingdom (51% of subjects), France (27%), and Germany (22%). At randomization, the median age was 4 months (range: 0 to 12 months); 49% of infants were less than or equal to 3 months; 24% were greater than 3 to less than or equal to 6 months, and 28% were greater than 6 months of age. Of these infants, 52% were male and 48% were female. Most subjects were term infants, with a gestational age at birth of greater than or equal to 37 weeks (85%). Half of the subjects were born during the RSV season. The majority of subjects (99%) in the BEYFORTUS group received their BEYFORTUS dose during the RSV season. The primary endpoint for Trial 09 was the overall incidence of RSV LRTI hospitalization caused by confirmed RSV infection, through the RSV season. Subjects were followed through the end of the RSV season for efficacy and through Day 365 for safety. The median efficacy follow-up time from intervention or randomization to the end of the RSV season was 2.3 months (range: 0 to 7.0 months) in the BEYFORTUS group and 2.0 months (range: 0 to 6.8 months) in the no intervention group. RSV LRTI hospitalizations occurred in 11 of 4,037 infants in the BEYFORTUS group (incidence rate=0.001) and in 60 of 4,021 infants in the no intervention group (incidence rate=0.006) through the RSV season, for an efficacy based on relative risk reduction of 83.2% (95% CI 67.8, 92.0)."],"pharmacodynamics":["12.2 Pharmacodynamics There is a positive correlation between a serum nirsevimab-alip AUC (based on clearance at baseline) above 12.8 mg*day/mL and a lower incidence of medically attended RSV lower respiratory tract infection (MA RSV LRTI). Following IM administration of nirsevimab-alip in adults, RSV neutralizing antibody levels in serum were approximately 4 times higher than baseline at 8 hours after nirsevimab-alip dosing, and maximum levels were reached by day 6 following IM administration of nirsevimab-alip in adults. The safety and effectiveness of BEYFORTUS have not been established in adults. Duration of Protection Based on clinical data, the duration of protection offered by a single dose of BEYFORTUS extends through 5 months."],"pharmacokinetics":["12.3 Pharmacokinetics The PK of nirsevimab-alip is dose-proportional following a single IM administration of doses ranging from 25 mg (0.5 times the lowest approved recommended dosage) to 200 mg in pediatric subjects. Following the recommended dose, the nirsevimab-alip serum exposures were similar in neonates and infants born during or entering their first RSV season (Trials 03 and 04), and in neonates and infants born at less than 35 weeks GA (including less than 29 weeks GA) in their first RSV season (Trial 05), and in pediatric subjects up to 24 months of age with CLD or CHD in their first and second RSV season (Trial 05). Absorption The estimated nirsevimab-alip absolute bioavailability is 84% and the median time (range) to maximum concentration is 6 (1, 28) days. Distribution The estimated nirsevimab-alip total volume of distribution is 477 mL, for an infant weighing 5 kg. Elimination The nirsevimab-alip terminal half-life is approximately 71 days and the estimated clearance is 3.42 mL/day for an infant weighing 5 kg. Metabolism Nirsevimab-alip is degraded into small peptides by catabolic pathways. Specific Populations No clinically significant differences in the pharmacokinetics of nirsevimab-alip were observed based on race or vulnerability to severe RSV disease (i.e., CLD, CHD, GA <29 weeks). The mean and median serum nirsevimab-alip concentrations in Trial 08 were lower than the concentrations in Trials 04 and 05. However, Trial 08 exposures were within the range shown to be effective in those who received the recommended dosage in Trials 03, 04, and 05 [see Pediatric Use (8.4) ] . Drug Interaction Studies No formal drug interaction studies have been performed with BEYFORTUS. Nirsevimab-alip is not predicted to be a substrate of, inhibitor or inducer of cytochrome P450 enzymes or transporter systems based on a mechanistic understanding of monoclonal antibodies. Clinical Studies Vaccines : There is limited experience with co-administration of BEYFORTUS with vaccines. In clinical trials, when BEYFORTUS was given concomitantly with routine childhood vaccines, the safety and reactogenicity profile of the co-administered regimen was similar to the childhood vaccines given alone."],"adverse_reactions":["6 ADVERSE REACTIONS Most common adverse reactions were rash (0.9%) and injection site reactions (0.3%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sanofi at 1-855-239-3678 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A total of 3,224 pediatric subjects received the recommended dose of BEYFORTUS in Phase 2 and Phase 3 clinical trials (Trials 03, 04, and 05) including 2,119 infants who were born at 35 weeks gestational age (GA) or older, and 1,105 infants who were born at less than 35 weeks GA. A total of 247 infants of any GA with chronic lung disease (CLD) of prematurity or hemodynamically significant congenital heart disease (CHD) in Trial 05 received the recommended dose of BEYFORTUS. Neonates and Infants Entering Their First RSV Season (Trial 03 and Trial 04) Trial 03 was a randomized, double-blind placebo-controlled trial conducted in preterm infants born at a GA of greater than or equal to 29 weeks to less than 35 weeks. Subjects were randomized 2:1 to receive BEYFORTUS (N=968) or placebo (N=479) by IM injection. All subjects randomized to BEYFORTUS received a single 50 mg IM dose regardless of body weight. Safety data in Trial 03 are presented only for the infants in the BEYFORTUS arm who received the recommended dose [infants who weighed less than 5 kg and who received a single dose of 50 mg BEYFORTUS IM (N=572) or placebo (N=288)]. Trial 04 was a Phase 3, randomized, double-blind, placebo-controlled trial conducted in late preterm and term infants born at greater than or equal to 35 weeks GA. Trial 04 enrolled subjects sequentially into two cohorts: the Primary Cohort was used for the primary efficacy analysis [see Clinical Studies (14.3) ] and for assessment of safety, and the Safety Cohort was used primarily for safety assessment. All subjects from both cohorts of Trial 04 were included in the safety analysis (BEYFORTUS N=1,997 and placebo N=997). Subjects in Trial 04 weighing less than 5 kg received a single 50 mg IM dose of BEYFORTUS and infants weighing greater than or equal to 5 kg received a single 100 mg IM dose. Infants who received the recommended dose in Trial 03 and infants in Trial 04 were pooled to evaluate the safety of BEYFORTUS (N=2,570) compared to placebo (N=1,284). At randomization, in this pooled Safety Population from Trials 03 and 04 cohorts, 22% of infants were born at less than 35 weeks GA, 10% of infants were GA greater than or equal to 35 weeks and less than 37 weeks; 68% were GA greater than or equal to 37 weeks; 52% were male; 57% were White; 15% were Black; 4% were American Indian/Alaskan native; 4% were Asian; 1% were Pacific Islander; and 19% were Other or Mixed Race; 30% were Hispanic or Latino; 73% were from Northern Hemisphere; and 53% weighed less than 5 kg. The median age was 2 months; 65% were less than or equal to 3 months; 28% were greater than 3 to less than or equal to 6 months, and 7% were greater than 6 months of age. (Refer to Sections 14.2 and 14.3, Clinical Studies, for a description of the efficacy populations in Trials 03 and 04). In both trials, infants received a single dose of IM BEYFORTUS or placebo on Study Day 1 and were monitored for at least 60 minutes post-dose. Subjects were followed for 360 days post-dose to assess safety. Adverse reactions were reported in 1.2% of subjects who received BEYFORTUS; most (97%) of adverse reactions were mild to moderate in intensity. Table 3 summarizes the adverse reactions that occurred in Trial 03 and Trial 04 (Safety Population) in subjects who received the recommended dose of BEYFORTUS. Table 3 Adverse Reactions Reported at an Incidence Higher Than Placebo in the Safety Population The Safety Population includes all subjects who received the recommended dose of BEYFORTUS in Trials 03 and 04: Primary and Safety cohorts from Trial 04; infants who weighed less than 5 kg and who received the recommended dose of BEYFORTUS (single 50 mg IM dose) in Trial 03. (Trials 03 and 04) Adverse Reaction BEYFORTUS N=2,570 % Placebo N=1,284 % Rash Rash was defined by the following grouped preferred terms: rash, rash macular, rash maculo-papular, rash papular. (occurring within 14 days post-dose) 0.9 0.6 Injection site reaction Injection site reaction was defined by the following grouped preferred terms: injection site reaction, injection site pain, injection site induration, injection site edema, injection site swelling. (occurring within 7 days post-dose) 0.3 0 Infants Born at <35 Weeks Gestational Age and Infants and Children with CLD of Prematurity or Hemodynamically Significant CHD (Trial 05) RSV Season One The safety of BEYFORTUS was evaluated in Trial 05, a randomized, double-blind, palivizumab-controlled multicenter trial in infants at high risk for severe RSV disease. These subjects were randomized 2:1 to receive BEYFORTUS (N=614) or palivizumab (N=304) by IM injection. The 614 infants who received BEYFORTUS included 128 preterm infants born at GA less than 29 weeks, 390 preterm infants who were born at 29 weeks or older to less than 35 weeks GA, and 96 late preterm and term infants born at 35 weeks GA or older. Among infants enrolled during their first RSV season, the number of infants with CLD of prematurity or hemodynamically significant CHD were overall 214 and 103, respectively, regardless of gestational age. Of these, 12 infants had both CLD and CHD. Subjects in Trial 05 weighing less than 5 kg received a single 50 mg IM dose of BEYFORTUS and infants weighing greater than or equal to 5 kg received a single 100 mg IM dose. BEYFORTUS was administered once on Study Day 1 followed by 4 monthly IM doses of placebo; palivizumab was administered IM monthly for 5 months. All subjects were monitored for at least 60 minutes post-dose. Subjects were followed for 360 days post-dose to assess safety. Adverse reactions reported among Trial 05 subjects who received BEYFORTUS in their first RSV season were similar to those reported in subjects who received BEYFORTUS in Trials 03 and 04. RSV Season Two (Subjects with CLD of Prematurity and Hemodynamically Significant CHD) Subjects with CLD of prematurity or hemodynamically significant CHD could continue in Trial 05 and receive BEYFORTUS or palivizumab prior to their second RSV season. All subjects who received BEYFORTUS in the first RSV season also received BEYFORTUS in the second RSV season (N=180). Subjects who received palivizumab in the first RSV season were re-randomized to receive BEYFORTUS (N=40) or palivizumab (N=42) in the second RSV season. Safety data were available for 150 days after dosing in children with CLD or CHD who received BEYFORTUS (N=220) or palivizumab (N=42) in their second RSV season. The safety profile of BEYFORTUS in these children during their second RSV season was consistent with the safety profile of BEYFORTUS observed during their first RSV season. Term and Preterm Infants Entering Their First RSV Season (Trial 09) The safety of BEYFORTUS was evaluated in Trial 09, a randomized open-label multicenter trial in 8,034 term and preterm infants (GA greater than or equal to 29 weeks) entering their first RSV season (not eligible for palivizumab), who received BEYFORTUS (N=4,016) or no intervention (N=4,018) for the prevention of RSV LRTI hospitalization. Subjects were followed for 365 days post-dose (BEYFORTUS arm) or post-randomization (no intervention arm) to assess safety. The safety profile of BEYFORTUS administered in the first RSV season was consistent with the safety profile of BEYFORTUS in the placebo-controlled Trials 03 and 04. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of BEYFORTUS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hypersensitivity reactions [see Warnings and Precautions (5.1) ] ."],"contraindications":["4 CONTRAINDICATIONS BEYFORTUS is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients [see Warnings and Precautions (5.1) and Description (11) ] . BEYFORTUS is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Interference with RT-PCR or Rapid Antigen Detection RSV Diagnostic Assays Nirsevimab-alip does not interfere with reverse transcriptase polymerase chain reaction (RT-PCR) or rapid antigen detection RSV diagnostic assays that employ commercially available antibodies targeting antigenic site I, II, or IV on the RSV fusion (F) protein. For immunological assay results which are negative when clinical observations are consistent with RSV infection, it is recommended to confirm using an RT-PCR-based assay."],"mechanism_of_action":["12.1 Mechanism of Action BEYFORTUS is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ] ."],"storage_and_handling":["Storage and Handling Store refrigerated between 36°F to 46°F (2°C to 8°C). BEYFORTUS may be kept at room temperature 68°F to 77°F (20°C to 25°C) for a maximum of 8 hours. After removal from the refrigerator, BEYFORTUS must be used within 8 hours or discarded. Store BEYFORTUS in original carton to protect from light until time of use. Do not freeze. Do not shake. Do not expose to heat."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action BEYFORTUS is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ] . 12.2 Pharmacodynamics There is a positive correlation between a serum nirsevimab-alip AUC (based on clearance at baseline) above 12.8 mg*day/mL and a lower incidence of medically attended RSV lower respiratory tract infection (MA RSV LRTI). Following IM administration of nirsevimab-alip in adults, RSV neutralizing antibody levels in serum were approximately 4 times higher than baseline at 8 hours after nirsevimab-alip dosing, and maximum levels were reached by day 6 following IM administration of nirsevimab-alip in adults. The safety and effectiveness of BEYFORTUS have not been established in adults. Duration of Protection Based on clinical data, the duration of protection offered by a single dose of BEYFORTUS extends through 5 months. 12.3 Pharmacokinetics The PK of nirsevimab-alip is dose-proportional following a single IM administration of doses ranging from 25 mg (0.5 times the lowest approved recommended dosage) to 200 mg in pediatric subjects. Following the recommended dose, the nirsevimab-alip serum exposures were similar in neonates and infants born during or entering their first RSV season (Trials 03 and 04), and in neonates and infants born at less than 35 weeks GA (including less than 29 weeks GA) in their first RSV season (Trial 05), and in pediatric subjects up to 24 months of age with CLD or CHD in their first and second RSV season (Trial 05). Absorption The estimated nirsevimab-alip absolute bioavailability is 84% and the median time (range) to maximum concentration is 6 (1, 28) days. Distribution The estimated nirsevimab-alip total volume of distribution is 477 mL, for an infant weighing 5 kg. Elimination The nirsevimab-alip terminal half-life is approximately 71 days and the estimated clearance is 3.42 mL/day for an infant weighing 5 kg. Metabolism Nirsevimab-alip is degraded into small peptides by catabolic pathways. Specific Populations No clinically significant differences in the pharmacokinetics of nirsevimab-alip were observed based on race or vulnerability to severe RSV disease (i.e., CLD, CHD, GA <29 weeks). The mean and median serum nirsevimab-alip concentrations in Trial 08 were lower than the concentrations in Trials 04 and 05. However, Trial 08 exposures were within the range shown to be effective in those who received the recommended dosage in Trials 03, 04, and 05 [see Pediatric Use (8.4) ] . Drug Interaction Studies No formal drug interaction studies have been performed with BEYFORTUS. Nirsevimab-alip is not predicted to be a substrate of, inhibitor or inducer of cytochrome P450 enzymes or transporter systems based on a mechanistic understanding of monoclonal antibodies. Clinical Studies Vaccines : There is limited experience with co-administration of BEYFORTUS with vaccines. In clinical trials, when BEYFORTUS was given concomitantly with routine childhood vaccines, the safety and reactogenicity profile of the co-administered regimen was similar to the childhood vaccines given alone. 12.4 Microbiology Mechanism of Action Nirsevimab-alip is a recombinant human IgG1κ monoclonal antibody that provides passive immunity by targeting the prefusion conformation of the RSV F protein. Nirsevimab-alip is long-acting due to a triple amino acid substitution (YTE) in the Fc region which increases binding to the neonatal Fc receptor and thereby extends serum half-life. Nirsevimab-alip binds to a conserved epitope in antigenic site Ø on the prefusion protein with dissociation constants K D = 0.12 nM and K D = 1.22 nM for RSV subtype A and B strains, respectively; it neutralizes RSV by inhibiting conformation changes in the F protein necessary for fusion of the viral and cellular membranes and viral entry. Antiviral Activity The cell culture neutralization activity of nirsevimab-alip against RSV was measured in a concentration-response model using cultured Hep-2 cells. Nirsevimab-alip neutralized clinical RSV isolates collected from global locations between 2003 and 2017 with median EC 50 values for RSV A of 21 pM (3.2 ng/mL) (n=70; range 3 pM [0.48 ng/mL] to 100 pM [15 ng/mL]) and for RSV B of 19 pM (2.9 ng/mL) (n=49; range 2 pM [0.3 ng/mL] to 398 pM [59.7 ng/mL]). Antiviral Resistance In Cell Culture Escape variants were selected following three passages in cell culture of RSV A2 and B9320 strains in the presence of nirsevimab-alip. Recombinant RSV A variants that showed reduced susceptibility to nirsevimab-alip compared with the reference strain included those with substitutions N67I+N208Y (103-fold reduction). Recombinant RSV B variants that showed reduced susceptibility to nirsevimab-alip included those with substitutions N208D (>90,000-fold change), N208S (>24,000-fold change), K68N+N201S (>13,000-fold change), and K68N+N208S (>90,000-fold change). All resistance-associated substitutions identified among neutralization escape variants were located in the nirsevimab-alip binding site (amino acids 62–69 and 196–212) and were shown to reduce binding affinity to RSV F protein. In Surveillance Trials Polymorphisms conferring large fold-reductions in susceptibility to nirsevimab-alip in isolates collected from 1956–2014 were not observed for RSV A and seen rarely (<1%) for RSV B, and included K65Q+K68N (1,239-fold change), K65Q+S211N (36-fold change), and L203I (3,005-fold change) substitutions. In prospective, observational, global molecular epidemiology studies (OUTSMART-RSV and INFORM-RSV) genetic diversity of RSV F protein sequences has remained low (most amino acids in both RSV A and RSV B >99% conserved). Variants harboring known nirsevimab-alip resistance-associated substitutions have been rare (<1%) and include RSV B substitutions K68Q (>369-fold change), N201T (>406-fold change) and N201T+I206M+Q209R (>418-fold change). Variants observed with reduced susceptibility include RSV A substitutions K68E (13-fold change), K68N (5-fold change), and S275F (6-fold change), and RSV B substitutions K68N (30-fold change), K68Q+I206M+Q209R (46-fold change), N201S (127-fold change) and N201S+I206M+Q209R (17-fold change). The clinical significance of these reductions in susceptibility is not known. From 2015 to 2021, most amino acid residues in the nirsevimab-alip binding site were highly conserved (>99%) at all positions in RSV A and 22 of the 25 positions in RSV B. Co-occurring substitutions I206M+Q209R in the nirsevimab-alip binding site that have become prevalent in RSV B since 2017 did not confer reduced susceptibility (<5-fold change) to nirsevimab-alip. The S211N substitution which has increased in prevalence also retains susceptibility to nirsevimab-alip, both individually and concurrently with I206M+Q209R. In Clinical Trials In Trial 04, Trial 05 and Trial 08 no known resistance-associated substitutions were identified at ≥25% frequency at any sampling time points. Phenotypic testing of novel substitutions is ongoing. In Trial 03 (who received a single dose of 50 mg BEYFORTUS), 2 of 40 subjects with RSV infections corresponding to any case definition had a variant containing nirsevimab-alip resistance-associated substitutions. The two subjects received less than the recommended nirsevimab-alip dose and had RSV B variants harboring I64T+K68E+I206M+Q209R co-occurring substitutions or an N208S substitution. I64T, K68E, and N208S substitutions individually have reduced susceptibility to nirsevimab-alip (fold changes: >496, >283, and >387, respectively). In Trial 04, an RSV B variant harboring binding site substitution L204S (no phenotypic data) concurrent with I206M+Q209R+S211N substitutions (<5-fold change) was detected at ≥25% frequency in one subject who received BEYFORTUS through Day 150. RSV B variants present at <25% frequency with I64T+K68E substitutions (>280-fold-change) and N208I substitution (>600-fold change) were seen in one subject each who received BEYFORTUS through Day 150 and an RSV B N201D substitution (>613-fold change) was observed in one subject after Day 150. In addition, an RSV A K209E substitution (135-fold change) was observed at <25% frequency in one subject after Day 150. Cross-resistance Limited data are available that show that variants resistant to nirsevimab-alip could have cross-resistance to palivizumab. Palivizumab retained full neutralization potency against resistance-associated substitutions identified in Trial 03 and Trial 04. Nirsevimab-alip retained activity against recombinant RSV harboring palivizumab resistance-associated substitutions identified in molecular epidemiology studies and in neutralization escape variants of palivizumab; S275F substitution had reduced susceptibility of 6-fold. 12.6 Immunogenicity The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of nirsevimab-alip or of other nirsevimab products. Of 572 subjects receiving the recommended dose of nirsevimab-alip in Trial 03, 3.3% (16/492) subjects were ADA-positive on Day 361. Among the 16 ADA-positive subjects, 94% (15/16) had ADA against YTE and none tested positive for neutralizing antibodies against nirsevimab-alip. In Trial 04, 5% (95/1778) of subjects were ADA-positive on Day 361, of whom 21% (20/95) had neutralizing antibodies and 77% (73/95) had ADA against YTE. In Trial 05, among subjects enrolled during their first RSV season, on Day 361, 6% (32/538) of subjects were positive for ADA. Among the 32 ADA-positive subjects, 6% (2/32) had neutralizing antibodies against nirsevimab-alip and 91% (29/32) had antibodies against the YTE substitution. Of 180 subjects who received nirsevimab-alip in two consecutive RSV seasons, on season 2 Day 361, 9% (13/144) of subjects were positive for ADA. Among the 13 ADA-positive subjects, 8% (1/13) had neutralizing antibodies against nirsevimab-alip and 62% (8/13) had antibodies against YTE. In Trial 08, among subjects receiving nirsevimab-alip in their first or second RSV season, 13% (9/67) of subjects were positive for ADA on Day 361. Among the 9 ADA-positive subjects, 11% (1/9) had neutralizing antibodies against nirsevimab-alip and 100% (9/9) were positive for ADA against YTE. In Trials 03, 04, 05, and 08 the effect of ADA on nirsevimab-alip serum concentrations through Day 151 could not be determined. Subjects who received BEYFORTUS who developed anti-nirsevimab-alip antibodies had reduced nirsevimab-alip concentrations at Day 361 (40% to 60% lower compared to subjects who received BEYFORTUS who did not develop anti-nirsevimab-alip antibodies). Because of the low occurrence of ADA and MA RSV LRTI in clinical trials, the effect of these ADA on effectiveness of BEYFORTUS is unknown."],"indications_and_usage":["1 INDICATIONS AND USAGE BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. BEYFORTUS is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. ( 1 ) Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following BEYFORTUS administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment. ( 5.1 ) 5.1 Hypersensitivity Reactions Including Anaphylaxis Serious hypersensitivity reactions have been reported following BEYFORTUS administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment. 5.2 Use in Individuals with Clinically Significant Bleeding Disorders As with any other IM injections, BEYFORTUS should be given with caution to infants and children with thrombocytopenia, any coagulation disorder, or to individuals on anticoagulation therapy."],"clinical_studies_table":["<table width=\"85%\"><caption>Table 4 Trials Conducted with BEYFORTUS for the Prevention of MA RSV LRTI</caption><col width=\"15%\" align=\"left\" valign=\"top\"/><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"35%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Trial</th><th styleCode=\"Rrule\">Population</th><th styleCode=\"Rrule\">Study Arms</th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"3\">GA gestational age; CLD chronic lung disease; CHD hemodynamically significant chronic heart disease</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">D5290C00003   (Trial 03)   NCT02878330</content></td><td styleCode=\"Rrule\">Infants born at &#x2265;29 to &lt;35 weeks GA entering their first RSV season</td><td styleCode=\"Rrule\">BEYFORTUS (N=969)<footnote>All subjects in Trial 03 were included in the efficacy analysis. All subjects in Trial 03 received 50 mg of BEYFORTUS IM injections regardless of body weight. The recommended BEYFORTUS dose in neonates and infants born during or entering their first RSV season is single IM 50 mg and 100 mg dose for those who weigh &lt;5 kg and &#x2265;5 kg, respectively <content styleCode=\"italics\">[see <linkHtml href=\"#S2.1\">Dosage and Administration (2.1)</linkHtml>]</content>.</footnote>  Placebo (N=484)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">D5290C00004   (Trial 04)   NCT03979313</content></td><td styleCode=\"Rrule\">Infants born at &#x2265;35 weeks GA entering their first RSV season</td><td styleCode=\"Rrule\"><content styleCode=\"bold\">Primary Cohort<footnote>The primary efficacy analysis for Trial 04 is based on subjects from the Primary Cohort. For Trial 04 safety population <content styleCode=\"italics\">[see <linkHtml href=\"#S6.1\">Adverse Reactions (6.1)</linkHtml>]</content>.</footnote>:</content>  BEYFORTUS (N=994)   Placebo (N=496)  <content styleCode=\"bold\">Safety Cohort<footnote>Trial 04 safety analysis included both Primary and Safety Cohorts <content styleCode=\"italics\">[see <linkHtml href=\"#S6.1\">Adverse Reactions (6.1)</linkHtml>]</content>.</footnote>:</content>  BEYFORTUS (N=1,015)   Placebo (N=507)</td></tr><tr><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">D5290C00005   (Trial 05)   NCT03959488</content></td><td styleCode=\"Rrule\">Infants born at &lt;35 weeks GA and infants born with CLD or CHD entering their first RSV season</td><td styleCode=\"Rrule\"><content styleCode=\"bold\">RSV Season One:</content>  BEYFORTUS (N=616)   Palivizumab (N=309)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"/><td styleCode=\"Rrule\">Infants with CLD or CHD only entering their second RSV season</td><td styleCode=\"Rrule\"><content styleCode=\"bold\">RSV Season Two:</content>  BEYFORTUS (N=220)   Palivizumab (N=42)</td></tr><tr><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">VAS00006   (Trial 09)   NCT05437510</content></td><td styleCode=\"Rrule\">Infants born &#x2265;29 weeks GA entering their first RSV season</td><td styleCode=\"Rrule\">BEYFORTUS (N=4,016)   No intervention (N=4,018)</td></tr></tbody></table>","<table width=\"85%\"><caption>Table 5 Incidence of MA RSV LRTI in Infants Born at &#x2265;29 Weeks to &lt;35 Weeks Through 150 Days Post Dose (Trial 03)</caption><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"10%\" align=\"center\" valign=\"middle\"/><col width=\"35%\" align=\"center\" valign=\"middle\"/><col width=\"35%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">N</th><th styleCode=\"Rrule\">Incidence % (n)</th><th styleCode=\"Rrule\">Efficacy<footnote>Efficacy for MA RSV LRTI based on relative risk reduction against placebo adjusted for age at randomization and hemisphere.</footnote> (95% CI)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">BEYFORTUS</td><td styleCode=\"Rrule\">969</td><td styleCode=\"Rrule\">2.6% (25)</td><td styleCode=\"Rrule\" rowspan=\"2\">70.1% (52.3, 81.2)<footnote>p-value =&lt;0.001.</footnote><footnote>In a post-hoc analysis of all randomized infants in Trial 03 weighing &lt;5 kg at baseline, and who received the recommended dose of BEYFORTUS, efficacy for MA RSV LRTI, based on relative risk reduction against placebo was 86.2% (95% CI 68.0, 94.0); efficacy for RSV LRTI with hospitalization based on relative risk reduction against placebo was 86.5% (95% CI 53.5, 96.1).</footnote></td></tr><tr><td styleCode=\"Lrule Rrule\">Placebo</td><td styleCode=\"Rrule\">484</td><td styleCode=\"Rrule\">9.5% (46)</td></tr></tbody></table>","<table width=\"85%\"><caption>Table 6 Incidence of MA RSV LRTI in Infants Born at &#x2265;35 Weeks Through 150 Days Post Dose (Trial 04)<footnote>The primary efficacy analysis for Trial 04 is based on subjects from the Primary Cohort.</footnote></caption><col width=\"20%\" align=\"left\" valign=\"middle\"/><col width=\"10%\" align=\"center\" valign=\"middle\"/><col width=\"35%\" align=\"center\" valign=\"middle\"/><col width=\"35%\" align=\"center\" valign=\"middle\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">N</th><th styleCode=\"Rrule\">Incidence % (n)</th><th styleCode=\"Rrule\">Efficacy<footnote>Efficacy for MA RSV LRTI based on relative risk reduction against placebo adjusted for age at randomization.</footnote> (95% CI)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">BEYFORTUS</td><td styleCode=\"Rrule\">994</td><td styleCode=\"Rrule\">1.2% (12)</td><td styleCode=\"Rrule\" rowspan=\"2\">74.9% (50.6, 87.3)<footnote>p-value =&lt;0.001.</footnote></td></tr><tr><td styleCode=\"Lrule Rrule\">Placebo</td><td styleCode=\"Rrule\">496</td><td styleCode=\"Rrule\">5.0% (25)</td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis, mutagenesis and reproductive toxicity studies have not been performed with BEYFORTUS."],"adverse_reactions_table":["<table width=\"85%\"><caption>Table 3 Adverse Reactions Reported at an Incidence Higher Than Placebo in the Safety Population<footnote>The Safety Population includes all subjects who received the recommended dose of BEYFORTUS in Trials 03 and 04: Primary and Safety cohorts from Trial 04; infants who weighed less than 5 kg and who received the recommended dose of BEYFORTUS (single 50 mg IM dose) in Trial 03.</footnote> (Trials 03 and 04)</caption><col width=\"32%\" align=\"left\" valign=\"top\"/><col width=\"32%\" align=\"center\" valign=\"top\"/><col width=\"36%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Adverse Reaction</th><th styleCode=\"Rrule\">BEYFORTUS   N=2,570   %</th><th styleCode=\"Rrule\">Placebo   N=1,284   %</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rash<footnote>Rash was defined by the following grouped preferred terms: rash, rash macular, rash maculo-papular, rash papular.</footnote> (occurring within 14 days post-dose)</td><td styleCode=\"Rrule\">0.9</td><td styleCode=\"Rrule\">0.6</td></tr><tr><td styleCode=\"Lrule Rrule\">Injection site reaction<footnote>Injection site reaction was defined by the following grouped preferred terms: injection site reaction, injection site pain, injection site induration, injection site edema, injection site swelling.</footnote> (occurring within 7 days post-dose)</td><td styleCode=\"Rrule\">0.3</td><td styleCode=\"Rrule\">0</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the child's caregiver to read the FDA-approved patient labeling (Patient Information). Hypersensitivity Reactions Including Anaphylaxis Inform the patient's caregiver of the signs and symptoms of potential hypersensitivity reactions, and advise the caregiver to seek medical attention immediately if the child experiences a hypersensitivity reaction to BEYFORTUS [see Warnings and Precautions (5.1) ] . Dosage and Administration Advise the caregiver that the child will receive one dose of BEYFORTUS by IM injection by a healthcare provider. If the child remains at increased risk for RSV, they may receive a second dose in the second RSV season [see Dosage and Administration (2.1) ]."],"spl_unclassified_section":["Manufactured by: Sanofi Pasteur Inc. Swiftwater, PA 18370 USA US License No. 1725 At: AstraZeneca Pharmaceuticals LP, Frederick, MD 21703 USA For patent information: https://www.sanofi.us/en/products-and-resources/patents BEYFORTUS is a registered trademark of the Sanofi group of companies."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Administer as an intramuscular injection. ( 2.1 ) Recommended dosage: Neonates and infants born during or entering their first RSV season: 50 mg if less than 5 kg in body weight. ( 2.1 ) 100 mg if greater than or equal to 5 kg in body weight. ( 2.1 ) Children who remain vulnerable through their second RSV season: 200 mg (2 × 100 mg injections). ( 2.1 ) 2.1 Recommended Dosage First RSV Season for Neonates and Infants For neonates and infants born during the RSV season, administer BEYFORTUS starting from birth. For neonates and infants born outside the RSV season, administer BEYFORTUS once prior to the start of the RSV season considering duration of protection provided by BEYFORTUS [see Clinical Pharmacology (12.2) ] . The recommended dosage of BEYFORTUS for neonates and infants born during or entering their first RSV season is based on body weight (see Table 1 ) and is administered as a single intramuscular (IM) injection. Table 1 Recommended Dosage of BEYFORTUS for the First RSV Season Body Weight at Time of Dosing Recommended Dosage Less than 5 kg 50 mg by IM injection 5 kg and greater 100 mg by IM injection Second RSV Season for Children Who Remain at Increased Risk for Severe RSV Disease For children up to 24 months of age, regardless of body weight, who remain at increased risk for severe RSV disease in their second RSV season, refer to Table 2 below for recommended dosage. Table 2 Recommended Dosage of BEYFORTUS for the Second RSV Season for Children Who Remain at Increased Risk for Severe RSV Disease Child's Age at Time of Dosing Recommended Dosage Up to 24 months of age Regardless of body weight 200 mg administered as two IM injections of (2 × 100 mg) First and Second RSV Season for Children Undergoing Cardiac Surgery with Cardiopulmonary Bypass For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose of BEYFORTUS is recommended as soon as the child is stable after surgery to ensure adequate nirsevimab-alip serum levels. The recommended dosage of BEYFORTUS is administered as an IM injection. First RSV season: If surgery is within 90 days after receiving BEYFORTUS, the additional dose should be based on body weight at the time of the additional dose. Refer to Table 1 for weight-based dosing. If more than 90 days have elapsed since receiving BEYFORTUS, the additional dose should be 50 mg regardless of body weight. Second RSV season: If surgery is within 90 days after receiving BEYFORTUS, the additional dose should be 200 mg, regardless of body weight. If more than 90 days have elapsed since receiving BEYFORTUS, the additional dose should be 100 mg, regardless of body weight. 2.2 Administration Instructions BEYFORTUS must be administered by a healthcare provider. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. BEYFORTUS is a clear to opalescent, colorless to yellow solution. Do not inject BEYFORTUS if the liquid is cloudy, discolored, or it contains large particles or foreign particulate matter. Do not use if the BEYFORTUS pre-filled syringe has been dropped or damaged, the security seal on the carton has been broken, or the expiration date has passed. BEYFORTUS is available in a 50 mg and a 100 mg pre-filled syringe. Check the labels on the BEYFORTUS carton and pre-filled syringe to ensure the correct 50 mg or 100 mg product is being used. Co-administration with Childhood Vaccines and Immunoglobulin Products BEYFORTUS can be given concomitantly with childhood vaccines [see Clinical Pharmacology (12.3) ] . When administered concomitantly with injectable vaccines, they should be given with separate syringes and at different injection sites. Do not mix BEYFORTUS with any vaccines or medications in the same syringe or vial. There is no information regarding co-administration of BEYFORTUS with other immunoglobulin products. Palivizumab should not be administered to infants who have already received BEYFORTUS in the same season. There are no data regarding substitution of BEYFORTUS for palivizumab once prophylaxis treatment is initiated with palivizumab for the RSV season. BEYFORTUS may be administered prior to or during the second RSV season to children up to 24 months of age who remain vulnerable to severe RSV disease, and who received palivizumab in their first RSV season [see Adverse Reactions (6.1) and Clinical Studies (14.3) ] . Administration Instructions for Single-Dose Pre-filled Syringe BEYFORTUS 50 mg (50 mg/0.5 mL) pre-filled syringe with a purple plunger rod. BEYFORTUS 100 mg (100 mg/mL) pre-filled syringe with a light blue plunger rod. Refer to Figure 1 for pre-filled syringe components. Figure 1 Luer Lock Syringe Components Step 1: Holding the Luer lock in one hand (avoid holding the plunger rod or syringe body), unscrew the syringe cap by twisting it counter-clockwise with the other hand. Step 2: Attach a Luer lock needle to the pre-filled syringe by gently twisting the needle clockwise onto the pre-filled syringe until slight resistance is felt. Step 3: Hold the syringe body with one hand and carefully pull the needle cover straight off with the other hand. Do not hold the plunger rod while removing the needle cover or the rubber stopper may move. Do not touch the needle or let it touch any surface. Do not recap the needle or detach it from the syringe. Step 4: Administer the entire contents of the BEYFORTUS pre-filled syringe as an IM injection, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used as an injection site because of the risk of damage to the sciatic nerve. Step 5: Discard syringe into a sharps container. If two injections are required, repeat Steps 1–5 in a different injection site. Image Image Figure 1"],"spl_product_data_elements":["BEYFORTUS nirsevimab NIRSEVIMAB NIRSEVIMAB HISTIDINE HISTIDINE HYDROCHLORIDE MONOHYDRATE ARGININE HYDROCHLORIDE SUCROSE POLYSORBATE 80 WATER BEYFORTUS nirsevimab NIRSEVIMAB NIRSEVIMAB HISTIDINE HISTIDINE HYDROCHLORIDE MONOHYDRATE ARGININE HYDROCHLORIDE SUCROSE POLYSORBATE 80 WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS BEYFORTUS is a clear to opalescent, colorless to yellow solution available as follows: Injection: 50 mg/0.5 mL in a single-dose pre-filled syringe. Injection: 100 mg/mL in a single-dose pre-filled syringe. Injection: 50 mg/0.5 mL in a single-dose pre-filled syringe. ( 3 ) 100 mg/mL in a single-dose pre-filled syringe. ( 3 )"],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: October 2025 PATIENT INFORMATION BEYFORTUS ® (Bay for tus) (nirsevimab-alip) injection, for intramuscular use What is BEYFORTUS? BEYFORTUS is a prescription medicine that is used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in: newborns and babies under 1 year of age born during or entering their first RSV season. children up to 24 months of age who remain at risk of severe RSV disease through their second RSV season. BEYFORTUS is an antibody that contains nirsevimab-alip which is used to help prevent RSV disease for 5 months. It is not known if BEYFORTUS is safe and effective in children older than 24 months of age. Your child should not receive BEYFORTUS if your child has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in BEYFORTUS. See the end of this Patient Information leaflet for a complete list of ingredients in BEYFORTUS. Before your child receives BEYFORTUS, tell your healthcare provider about all of your child's medical conditions, including if your child: has ever had a reaction to BEYFORTUS. has bleeding or bruising problems. If your child has a problem with bleeding or bruises easily, an injection could cause a problem. Tell your child's healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your infant should not receive a medicine called palivizumab if they have already received BEYFORTUS in the same RSV season. How is BEYFORTUS given? BEYFORTUS is given as an injection, usually in the thigh (leg) muscle, by your child's healthcare provider. Your child should receive BEYFORTUS before or during the RSV season. RSV season is the time of year when RSV infections are most common, usually occurring fall through spring. Your healthcare provider can tell you when the RSV season starts in your area. Your child may still get RSV disease after receiving BEYFORTUS . Talk to your child's healthcare provider about what symptoms to look for. If your child has heart surgery, your child's healthcare provider may need to give your child an additional BEYFORTUS injection soon after surgery. What are the possible side effects of BEYFORTUS? Serious allergic reactions have happened with BEYFORTUS. Get medical help right away if your child has any of the following signs or symptoms of a serious allergic reaction: swelling of the face, mouth, or tongue difficulty swallowing or breathing unresponsiveness bluish color of skin, lips or under fingernails muscle weakness severe rash, hives or itching The most common side effects of BEYFORTUS include rash, and pain, swelling or hardness at the site of your child's injection. These are not all of the possible side effects of BEYFORTUS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of BEYFORTUS. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about BEYFORTUS that is written for health professionals. What are the ingredients in BEYFORTUS? Active ingredient: nirsevimab-alip Inactive ingredients: arginine hydrochloride, histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose and water for injection. Manufactured by: Sanofi Pasteur Inc. Swiftwater, PA 18370 USA US License No. 1725 At: AstraZeneca Pharmaceuticals LP, Frederick, MD 21703 USA BEYFORTUS is a registered trademark of the Sanofi group of companies. For more information, go to https://www.Beyfortus.com or call 1-855-239-3678 (1-855-BEYFORTUS)."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS The safety and effectiveness of BEYFORTUS in children older than 24 months of age have not been established. ( 8.4 ) 8.1 Pregnancy BEYFORTUS is not indicated for use in females of reproductive potential. 8.2 Lactation BEYFORTUS is not indicated for use in females of reproductive potential. 8.4 Pediatric Use The safety and effectiveness of BEYFORTUS have been established for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. The safety and efficacy of BEYFORTUS for this indication and populations are discussed throughout the labeling. Use of BEYFORTUS for this indication is supported by evidence from adequate and well-controlled studies in neonates and infants from birth up to 12 months of age with additional pharmacokinetic and safety data in children up to 24 months of age [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14) ]. Use of BEYFORTUS in this population is supported by the following: - Trial 03, a randomized, double-blind, placebo-controlled multicenter trial for the prevention of MA RSV LRTI conducted in preterm infants born at GA greater than or equal to 29 weeks and less than 35 weeks entering their first RSV season; - Trial 04, a double-blind, placebo-controlled multicenter trial, for the prevention of MA RSV LRTI in term and late preterm infants GA greater than or equal to 35 weeks entering their first RSV season; - Trial 05, a Phase 2/3 randomized, double-blind, palivizumab-controlled multicenter trial in pediatric subjects born less than 35 weeks GA and infants with CLD of prematurity or hemodynamically significant CHD entering their first or second RSV season. In addition, BEYFORTUS was evaluated in an open-label, uncontrolled, single-dose trial (Trial 08) in 100 infants and children who were less than or equal to 24 months of age, who received BEYFORTUS in their first or second RSV season, and who had a wide variety of underlying diseases or treatments resulting in immune compromise. The safety profile of BEYFORTUS administered in Trial 08 was consistent with the safety profile of other trials of BEYFORTUS in infants and children [see Clinical Pharmacology (12.3) ]. Trial 09 is a Phase 3b randomized, open-label trial of BEYFORTUS compared to no intervention for the prevention of hospitalization in term and preterm infants (GA greater than or equal to 29 weeks) born during or entering their first RSV season [see Adverse Reactions (6.1) and Clinical Studies (14.5) ]. The safety and effectiveness of BEYFORTUS have not been established in children older than 24 months of age."],"dosage_and_administration_table":["<table width=\"80%\" ID=\"Table1\"><caption>Table 1 Recommended Dosage of BEYFORTUS for the First RSV Season</caption><col width=\"55%\" align=\"left\" valign=\"top\"/><col width=\"45%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Body Weight at Time of Dosing</th><th styleCode=\"Rrule\">Recommended Dosage</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Less than 5 kg</td><td styleCode=\"Rrule\">50 mg by IM injection </td></tr><tr><td styleCode=\"Lrule Rrule\">5 kg and greater</td><td styleCode=\"Rrule\">100 mg by IM injection</td></tr></tbody></table>","<table width=\"80%\"><caption>Table 2 Recommended Dosage of BEYFORTUS for the Second RSV Season for Children Who Remain at Increased Risk for Severe RSV Disease</caption><col width=\"30%\" align=\"left\" valign=\"top\"/><col width=\"70%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Child&apos;s Age at Time of Dosing</th><th styleCode=\"Rrule\">Recommended Dosage</th></tr></thead><tbody><tr><td styleCode=\"Lrule Rrule\">Up to 24 months of age<footnote>Regardless of body weight</footnote></td><td styleCode=\"Rrule\">200 mg administered as two IM injections of (2 &#xD7; 100 mg)</td></tr></tbody></table>","<table width=\"80%\" styleCode=\"Noautorules\"><col width=\"2%\" align=\"left\" valign=\"top\"/><col width=\"48%\" align=\"left\" valign=\"top\"/><col width=\"2%\" align=\"left\" valign=\"top\"/><col width=\"48%\" align=\"left\" valign=\"top\"/><tbody><tr><td> </td><td>BEYFORTUS 50 mg (50 mg/0.5 mL) pre-filled syringe with a purple plunger rod.</td><td> </td><td>BEYFORTUS 100 mg (100 mg/mL) pre-filled syringe with a light blue plunger rod.</td></tr><tr><td> </td><td><renderMultiMedia referencedObject=\"MM1\"/></td><td> </td><td><renderMultiMedia referencedObject=\"MM2\"/></td></tr></tbody></table>"],"spl_patient_package_insert_table":["<table width=\"100%\"><col width=\"3%\" align=\"left\" valign=\"top\"/><col width=\"46%\" align=\"left\" valign=\"top\"/><col width=\"31%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"left\" valign=\"top\"/><tfoot><tr><td align=\"left\" colspan=\"3\">This Patient Information has been approved by the U.S. Food and Drug Administration.</td><td align=\"right\">Revised: October 2025</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\" align=\"center\"><content styleCode=\"bold\">PATIENT INFORMATION   BEYFORTUS<sup>&#xAE;</sup> (Bay for tus)   (nirsevimab-alip)   injection, for intramuscular use</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">What is BEYFORTUS?</content>  BEYFORTUS is a prescription medicine that is used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in: <list listType=\"unordered\" styleCode=\"disc\"><item>newborns and babies under 1 year of age born during or entering their first RSV season.</item><item>children up to 24 months of age who remain at risk of severe RSV disease through their second RSV season.</item></list> BEYFORTUS is an antibody that contains nirsevimab-alip which is used to help prevent RSV disease for 5 months.   It is not known if BEYFORTUS is safe and effective in children older than 24 months of age.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Your child should not receive BEYFORTUS if your child</content> has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in BEYFORTUS. See the end of this Patient Information leaflet for a complete list of ingredients in BEYFORTUS.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">Before your child receives BEYFORTUS, tell your healthcare provider about all of your child&apos;s medical conditions, including if your child:</content><list listType=\"unordered\" styleCode=\"disc\"><item>has ever had a reaction to BEYFORTUS.</item><item>has bleeding or bruising problems. If your child has a problem with bleeding or bruises easily, an injection could cause a problem.</item></list><content styleCode=\"bold\">Tell your child&apos;s healthcare provider about all the medicines your child takes,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your infant should not receive a medicine called palivizumab if they have already received BEYFORTUS in the same RSV season.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">How is BEYFORTUS given?</content><list listType=\"unordered\" styleCode=\"disc\"><item>BEYFORTUS is given as an injection, usually in the thigh (leg) muscle, by your child&apos;s healthcare provider.</item><item><content styleCode=\"bold\">Your child should receive BEYFORTUS before or during the RSV season.</content> RSV season is the time of year when RSV infections are most common, usually occurring fall through spring. Your healthcare provider can tell you when the RSV season starts in your area.</item><item><content styleCode=\"bold\">Your child may still get RSV disease after receiving BEYFORTUS</content>. Talk to your child&apos;s healthcare provider about what symptoms to look for.</item><item>If your child has heart surgery, your child&apos;s healthcare provider may need to give your child an additional BEYFORTUS injection soon after surgery.</item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">What are the possible side effects of BEYFORTUS?</content><list listType=\"unordered\" styleCode=\"disc\"><item><content styleCode=\"bold\">Serious allergic reactions</content> have happened with BEYFORTUS.</item><item>Get medical help right away if your child has any of the following signs or symptoms of a serious allergic reaction:</item></list></td></tr><tr><td styleCode=\"Lrule\"/><td><list listType=\"unordered\" styleCode=\"circle\"><item>swelling of the face, mouth, or tongue</item><item>difficulty swallowing or breathing</item><item>unresponsiveness</item></list></td><td styleCode=\"Rrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"circle\"><item>bluish color of skin, lips or under fingernails</item><item>muscle weakness</item><item>severe rash, hives or itching</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">The most common side effects of BEYFORTUS include</content> rash, and pain, swelling or hardness at the site of your child&apos;s injection.   These are not all of the possible side effects of BEYFORTUS.   Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">General information about the safe and effective use of BEYFORTUS.</content>  Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about BEYFORTUS that is written for health professionals.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\"><content styleCode=\"bold\">What are the ingredients in BEYFORTUS?</content> <content styleCode=\"bold\">Active ingredient:</content> nirsevimab-alip  <content styleCode=\"bold\">Inactive ingredients:</content> arginine hydrochloride, histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose and water for injection.   Manufactured by: Sanofi Pasteur Inc. Swiftwater, PA 18370 USA   US License No. 1725   At: AstraZeneca Pharmaceuticals LP, Frederick, MD 21703 USA   BEYFORTUS is a registered trademark of the Sanofi group of companies.   For more information, go to https://www.Beyfortus.com or call 1-855-239-3678 (1-855-BEYFORTUS).</td></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Carton NDC 49281-575-15 Rx only Beyfortus ® (nirsevimab-alip) Injection 50 mg / 0.5 mL For Intramuscular Injection Only Store the pre-filled syringe in original carton to protect from light until time of use. Must be administered by a healthcare provider. Five 0.5 mL single-dose prefilled syringes sanofi PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Carton","PRINCIPAL DISPLAY PANEL - 1 mL Syringe Carton NDC 49281-574-15 Rx only Beyfortus ® (nirsevimab-alip) Injection 100 mg/mL For Intramuscular Injection Only Store the pre-filled syringe in original carton to protect from light until time of use. Must be administered by a healthcare provider. Five 1 mL single-dose prefilled syringes sanofi PRINCIPAL DISPLAY PANEL - 1 mL Syringe Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis, mutagenesis and reproductive toxicity studies have not been performed with BEYFORTUS."]},"tags":[{"label":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody","category":"class"},{"label":"Monoclonal Antibody","category":"modality"},{"label":"J06BD08","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","category":"indication"},{"label":"Astrazeneca Ab","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"rash","drugRate":"0.9%","_validated":true,"placeboRate":"0.6%"},{"effect":"injection site reaction","drugRate":"0.3%","_validated":true,"placeboRate":""}],"contraindications":["BEYFORTUS is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients."],"specialPopulations":{"Pregnancy":"BEYFORTUS is not indicated for use in females of reproductive potential.","Paediatric use":"The safety and effectiveness of BEYFORTUS have been established for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season."}},"trials":[],"aliases":[],"company":"AstraZeneca","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NIRSEVIMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:13:10.808536+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Nirsevimab","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:13:17.573112+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:13:16.326567+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:13:10.921117+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:13:04.418497+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIRSEVIMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:13:16.540814+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:03.688909+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:03.688943+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:03.688948+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action BEYFORTUS is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ] .","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:25.100703+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Fusion glycoprotein F0 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:13:17.573054+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297575/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:13:17.239373+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS Most common adverse reactions were rash (0.9%) and injection site reactions (0.3%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sanofi at 1-855-239-3678 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:30.453362+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:40.498167+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761328","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:03.688951+00:00"}},"allNames":"beyfortus","offLabel":[],"synonyms":["nirsevimab","beyfortus","MEDI8897","nirsevimab-alip"],"timeline":[{"date":"2022-10-31","type":"positive","source":"DrugCentral","milestone":"EMA approval (Astrazeneca Ab)"},{"date":"2023-07-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Astrazeneca Ab)"}],"approvals":[{"date":"2022-10-31","orphan":false,"company":"ASTRAZENECA AB","regulator":"EMA"},{"date":"2023-07-17","orphan":false,"company":"ASTRAZENECA AB","regulator":"FDA"}],"brandName":"Beyfortus","ecosystem":[{"indication":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"RSV","novelty":"Follow-on","moaClass":"Fusion Protein Inhibitors","modality":"Monoclonal antibody","drugClass":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","explanation":"BEYFORTUS works by using a monoclonal antibody to combat Respiratory Syncytial Virus (RSV). This antibody binds to RSV and helps prevent the virus from infecting cells.","oneSentence":"BEYFORTUS is a monoclonal antibody that targets RSV.","technicalDetail":"Beyfortus is a human monoclonal antibody that targets the F protein of RSV, preventing viral attachment and fusion with host cells, thereby inhibiting the replication of the virus."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Nirsevimab","title":"Nirsevimab","extract":"Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.","wiki_history":"== History ==\nThe opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency was based on data from two randomized, double-blind, placebo-controlled multicenter clinical trials that investigated the efficacy and safety of nirsevimab in healthy preterm (premature) and full-term infants entering their first RSV season. The studies demonstrated that nirsevimab prevents lower respiratory tract infection caused by RSV requiring medical attention (such as bronchiolitis and pneumonia) in term and preterm infants during their first RSV season.\n\nThe safety of nirsevimab was also evaluated in a phase II/III, randomized, double‑blind, multi-center trial in infants who were born five or more weeks prematurely (less than 35 weeks gestation) at higher risk for severe RSV disease and infants with chronic lung disease of prematurity (i.e. long-term respiratory problems faced by babies born prematurely) or congenital heart disease. The results of this study showed that nirsevimab had a similar safety profile compared to palivizumab (Synagis).\n\nThe US Food and Drug Administration (FDA) evaluated the safety and efficacy of nirsevimab based on three trials, two of which were randomized, double-blind, placebo-controlled, multicenter clinical trials (Trials 03, 04 and 05). The key measure of efficacy was the incidence of medically attended RSV lower respiratory tract infection (MA RSV LRTI), evaluated during the 150 days after nirsevimab administration. MA RSV LRTI included all health care provider visits (physician office, urgent care, emergency room visits and hospitalization) for lower respiratory tract disease with worsening clinical severity and a positive RSV test. \n\nTrial 03 included 1,453 preterm infants (born at greater than or equal to 29 weeks of gestational age up to less than 35 weeks of gestation) who were born during or entering their first RSV season. Of the 1,453 preterm infants in the trial, 969 received a single dose of nirsevimab an","wiki_society_and_culture":"== Society and culture ==\n=== Legal status ===\nIn September 2022, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended to grant a marketing authorization for Beyfortus for the prevention of RSV lower respiratory tract disease in newborns and infants. Beyfortus was reviewed under EMA's accelerated assessment program. In November 2022, nirsevimab was approved for medical use in the European Union, and the United Kingdom.\nIt was approved in Canada in April 2023, and in the United States in July 2023."},"commercial":{"launchDate":"2023","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2023-07-17, ASTRAZENECA AB)","annualRevenue":800,"revenueSource":"Verified: Sanofi AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5698","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NIRSEVIMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIRSEVIMAB","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Nirsevimab","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:06:11.727315","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:13:41.464508+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[{"form":"INJECTION","route":"INTRAMUSCULAR","company":"Sanofi Pasteur Inc.","brandName":"BEYFORTUS","isOriginal":false,"marketingStatus":"BLA"}],"competitors":[{"drugName":"palivizumab","drugSlug":"palivizumab","fdaApproval":"1998-06-19","relationship":"same-class"},{"drugName":"ansuvimab","drugSlug":"ansuvimab","fdaApproval":"2020-12-21","relationship":"same-class"},{"drugName":"casirivimab","drugSlug":"casirivimab","fdaApproval":"2020-11-21","relationship":"same-class"},{"drugName":"imdevimab","drugSlug":"imdevimab","fdaApproval":"2020-11-21","relationship":"same-class"}],"genericName":"nirsevimab","indications":{"approved":[{"name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","source":"DrugCentral","snomedId":55735004,"regulator":"FDA","eligibility":{"Neonates and infants born during or entering their first RSV season":"","Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season":""}}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"palivizumab","brandName":"palivizumab","genericName":"palivizumab","approvalYear":"1998","relationship":"same-class"},{"drugId":"ansuvimab","brandName":"ansuvimab","genericName":"ansuvimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"casirivimab","brandName":"casirivimab","genericName":"casirivimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"imdevimab","brandName":"imdevimab","genericName":"imdevimab","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02878330","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.","status":"COMPLETED","sponsor":"MedImmune LLC","isPivotal":true,"startDate":"2016-11-03","conditions":["Respiratory Syncytial Virus Infections"],"enrollment":1453,"completionDate":"2018-12-06"},{"nctId":"NCT03959488","phase":"PHASE2,PHASE3","title":"A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"startDate":"2019-07-30","conditions":["Respiratory Syncytial Virus Infections"],"enrollment":925,"completionDate":"2023-01-20"},{"nctId":"NCT03979313","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"startDate":"2019-07-23","conditions":["Respiratory Syncytial Virus Infections"],"enrollment":3012,"completionDate":"2023-03-21"},{"nctId":"NCT05110261","phase":"PHASE3","title":"Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-24","conditions":["Lower Respiratory Tract Infection"],"enrollment":800,"completionDate":"2025-11-24"},{"nctId":"NCT06551506","phase":"PHASE4","title":"The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-19","conditions":["Respiratory Syncytial Virus Infection"],"enrollment":181,"completionDate":"2026-05-31"},{"nctId":"NCT07109297","phase":"PHASE4","title":"Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-07-31","conditions":["RSV Immunization"],"enrollment":110,"completionDate":"2026-06-30"},{"nctId":"NCT07158814","phase":"PHASE4","title":"Safety of RSV Preventive Monoclonal Antibody","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-10-02","conditions":["Fever","Adverse Event Following Immunisation"],"enrollment":524,"completionDate":"2027-04"},{"nctId":"NCT07382219","phase":"","title":"Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants","status":"COMPLETED","sponsor":"Han Tongyan","startDate":"2025-08-01","conditions":["RSV Infections","Lower Respiratory Tract Infections"],"enrollment":816,"completionDate":"2025-10-31"},{"nctId":"NCT07363837","phase":"PHASE1,PHASE2","title":"Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2026-01-15","conditions":["Respiratory Syncytial Virus (RSV)"],"enrollment":36,"completionDate":"2027-03-31"},{"nctId":"NCT07317141","phase":"","title":"The Effectiveness of Early Immunisation With Nirsevimab on Preschool Wheezing in France, Based on an Analysis of Data From the French Health System Database.","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-01","conditions":["Infant Wheeze","Preschool Age Children","Asthma Childhood"],"enrollment":218000,"completionDate":"2029-06-01"},{"nctId":"NCT07279298","phase":"","title":"Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV","status":"NOT_YET_RECRUITING","sponsor":"Bogotá District Health Secretariat","startDate":"2026-02-01","conditions":["Respiratory Syncytial Virus Infections","Severe Acute Respiratory Infection","Bronchiolitis, Viral","Viral Respiratory Tract Infection"],"enrollment":1097,"completionDate":"2027-07-31"},{"nctId":"NCT07200206","phase":"","title":"A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-10-02","conditions":["Respiratory Syncytial Virus"],"enrollment":3000,"completionDate":"2029-09-26"},{"nctId":"NCT07106918","phase":"EARLY_PHASE1","title":"A Clinical Trial of SIBP-A16 Injection in Healthy Adults","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-08-17","conditions":["Respiratory Syncytial Virus (RSV)"],"enrollment":140,"completionDate":"2027-04-30"},{"nctId":"NCT05743881","phase":"PHASE1","title":"A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-02-15","conditions":["Respiratory Syncytial Virus","Human Metapneumovirus"],"enrollment":186,"completionDate":"2026-09-30"},{"nctId":"NCT07232706","phase":"PHASE3","title":"Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2026-01","conditions":["RSV Immunization"],"enrollment":1000,"completionDate":"2029-01"},{"nctId":"NCT06325332","phase":"","title":"BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-01","conditions":["Respiratory Syncytial Virus"],"enrollment":49680,"completionDate":"2025-06-30"},{"nctId":"NCT05437510","phase":"PHASE3","title":"Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-08-08","conditions":["RSV Immunization","Healthy Volunteer"],"enrollment":8057,"completionDate":"2025-04-09"},{"nctId":"NCT07177508","phase":"","title":"First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory","status":"COMPLETED","sponsor":"Nicola Irwin","startDate":"2024-12-01","conditions":["Respiratory Syncytial Viral (RSV) Infection","Respiratory Syncytial Virus Hospitalizations","Respiratory Syncytial Virus Prevention"],"enrollment":2355,"completionDate":"2025-07-30"},{"nctId":"NCT06030505","phase":"","title":"Effectiveness of Nirsevimab in Children Hospitalised With RSV Bronchiolitis","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2023-10-15","conditions":["Bronchiolitis, Viral"],"enrollment":1140,"completionDate":"2023-12-29"},{"nctId":"NCT06172660","phase":"","title":"Real-World Effectiveness of Perinatal RSV Immunoprophylaxis","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-10-28","conditions":["RSV Infection"],"enrollment":3750,"completionDate":"2028-12-30"},{"nctId":"NCT07041190","phase":"PHASE3","title":"Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.","status":"NOT_YET_RECRUITING","sponsor":"PENTA Foundation","startDate":"2025-09","conditions":["RSV Immunization"],"enrollment":1500,"completionDate":"2028-12"},{"nctId":"NCT06881953","phase":"","title":"Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-06-17","conditions":["RSV Infection"],"enrollment":400,"completionDate":"2025-12-17"},{"nctId":"NCT06824207","phase":"","title":"Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-13","conditions":["Respiratory Syncytial Virus Immunization"],"enrollment":2400,"completionDate":"2026-05-30"},{"nctId":"NCT06993753","phase":"","title":"Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Griffith University","startDate":"2024-04-15","conditions":["Respiratory Syncytial Viral (RSV) Infections"],"enrollment":4350,"completionDate":"2027-03-31"},{"nctId":"NCT06042049","phase":"PHASE3","title":"A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-27","conditions":["Respiratory Syncytial Virus Infections"],"enrollment":33,"completionDate":"2025-08-15"},{"nctId":"NCT06856967","phase":"","title":"Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2024-12-04","conditions":["Respiratory Synctial Virus Infections"],"enrollment":138,"completionDate":"2025-04"},{"nctId":"NCT06636955","phase":"","title":"Viral Epidemiology of Bronchiolitis After Nirsevimab Implementation and Respiratory Evolution in Infants","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-10-07","conditions":["Acute Bronchiolitis"],"enrollment":900,"completionDate":"2028-12-31"},{"nctId":"NCT06185647","phase":"","title":"Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis","status":"COMPLETED","sponsor":"Hôpital Armand Trousseau","startDate":"2023-10-14","conditions":["Bronchiolitis","Respiratory Syncytial Virus (RSV)","Immunization; Infection"],"enrollment":4924,"completionDate":"2024-02-29"},{"nctId":"NCT06511687","phase":"","title":"Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)","status":"RECRUITING","sponsor":"Instituto Sistemas Complejos de Ingeniería","startDate":"2024-04-01","conditions":["RSV"],"enrollment":160000,"completionDate":"2024-10-01"},{"nctId":"NCT06180993","phase":"","title":"Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization","status":"RECRUITING","sponsor":"Federico Martinón Torres","startDate":"2023-09-25","conditions":["RSV Infection"],"enrollment":42000,"completionDate":"2026-10-31"},{"nctId":"NCT04484935","phase":"PHASE2","title":"Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-19","conditions":["RSV Infection"],"enrollment":100,"completionDate":"2023-02-17"},{"nctId":"NCT04840849","phase":"PHASE1","title":"Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-06-22","conditions":["Evaluate PK Profile"],"enrollment":24,"completionDate":"2021-11-18"}],"_emaApprovals":[{"date":"2022-10-31","status":"Authorised","company":"ASTRAZENECA AB"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02878330","NCT03979313","NCT03959488"],"administration":{"route":"Intramuscular","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"BEYFORTUS"}]},"crossReferences":{"MMSL":"41819","NDDF":"019497","UNII":"VRN8S9CW5V","INN_ID":"10780","RXNORM":"2642401","UMLSCUI":"C5418478","chemblId":"CHEMBL4297575","ChEMBL_ID":"CHEMBL4297575","KEGG_DRUG":"D11380","DRUGBANK_ID":"DB16258","MESH_SUPPLEMENTAL_RECORD_UI":"C000709769"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2023-","companyName":"AstraZeneca","relationship":"Original Developer"}],"pharmacokinetics":{"source":"FDA label","halfLife":"71 days"},"publicationCount":535,"therapeuticAreas":["Infectious Disease"],"_revenueScrapedAt":"2026-04-08 13:57:48.689353+00","atcClassification":{"source":"DrugCentral","atcCode":"J06BD08","allCodes":["J06BD08"]},"biosimilarFilings":[],"originalDeveloper":"Astrazeneca Ab","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Monoclonal antibody","firstApprovalDate":"2023","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-07-17T00:00:00.000Z","mah":"ASTRAZENECA AB","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-04-07T00:00:00.000Z","mah":"ASTRAZENECA AB","brand_name_local":null,"application_number":"BLA761328"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":13,"withResults":5},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:13:41.464508+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}